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The paper describes the catalytic activity of butyrylcholinesterase (BuChE) measured in plasma, liver, 
white adipose tissue, heart, and brain of rats intraperitoneally administered a single non–lethal dose of 
cycloheximide (2.0 mg/kg body weight; CHM). The BuChE assay was performed on rats of both sexes 
either administered CHM or saline (controls), and killed 2, 3, 4, 5, 10 days later. A significant decrease of 
BuChE catalytic activity was observed in all tested tissues except plasma. In animals of both sexes, the 
lowest BuChE catalytic activity was found in the liver (2–6%), while it was higher in white adipose tissue, 
heart, and brain. However, the respective values remained significantly different from controls (33–67%, 
49–62%, and 14–71% in males, and 24–82%, 72–86%, and 33–67% in females). Since there was no effect 
of CHM on BuChE catalytic activity in plasma, the data suggest that CHM inhibits the synthesis of BuChE 
rather than its active site.
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The toxicological importance of butyryl cho-
linesterase (BuChE: EC 3.1.1.8, acylcholine acylhydro-
lase, plasma cholinesterase) is evident in the fact that 
the diagnosis of poisoning by organophosphorous 
compounds (OPs) relies on clinical symptoms and 
laboratory tests for plasma BuChE and red cell ace-
tylcholinesterase (AChE: EC 3.1.1.7) catalytic activity. 
Butyrylcholinesterase is synthesized in the liver and is 
released in blood (1), but some authors (2) propose 
that its synthesis is not limited to the liver alone. The 
enzyme has been found in the small intestine, smooth 
muscle, adipose tissue, heart, and white matter of the 
brain. It is not known whether the catalytic activity of 
BuChE in these tissues contributes to the enzyme 
activity in plasma. So far, BuChE has no known bio-
logical substrate in the mammals (3), but it hydrolyses 
a variety of esters of choline including butyrylcholine, 
butyrylthiocholine, propionylthiocholine (4, 5). Butyryl-
cholinesterase is clinically important inasmuch as it 
hydrolyses the short–acting muscle relaxant succinyl-
choline and the ester type of local anaesthetics (5, 6). 
Although the physiological function of BuChE is not 
known, it was suggested to be a precursor of AChE 
in the nervous system, and that it contributed to the 
integrity of the myelin sheath of the central axons (7). 
Some authors suggest that BuChE plays a role in lipid 
and lipoprotein metabolism (8–10).
Cycloheximide (CHM) (Figure 1) is an antibiotic 
substance obtained from streptomycin–producing 
strains of Streptomyces griseus (11). Cycloheximide 
had been used in the treatment of cryptococcal 
infections (Cryptococcus neoformans) in humans 
before the development of amphotericin B. 
Cycloheximide has antifungal properties and has 
commercially been used in the USA to treat various 
fungal infections of plants and to regulate plant growth 
(11, 12). Therefore, to workers in agriculture, CHM 
presents a serious risk of poisoning.
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Cycloheximide is highly toxic (rat oral LD50 is 2.7 
mg/kg, intraperitoneal LD50 is 3.7 mg/kg) and strongly 
inhibits protein synthesis in mammals and mammalian 
cell culture systems (13, 14). However, Devasagayam 
and co–workers (15) observed that CHM (2.0 mg/kg 
b.w.) induced the synthesis of certain microsomal 
proteins of the rough endoplasmatic reticulum in the 
rat liver within the first two hours. The reversal, that 
is, the significant inhibition of the synthesis occurred 
in the 24 hours that followed.
Generally, there are few data about the influence 
of CHM on BuChE activity. The results of Gupta and 
Dettbarn (16) have shown that CHM (0.5 mg/kg) 
administered to rats subcutaneously for four days 
did not alter AChE and BuChE catalytic activities 
in the brain and muscle. However, the total protein 
synthesis in the brain, muscle, liver and kidney 
significantly dropped.
The inhibition of protein synthesis by CHM and 
the toxicological and pharmacological importance of 
BuChE encouraged us to investigate how a non–lethal 
CHM dose can affect BuChE catalytic activity in the 
liver and other tissues. Since BuChE catalytic activity 
is a good parameter of exposure to various chemicals 
(organophosphorus and carbamate esters), the other 
aim of our study was to see whether it could be used 
as an indicator of CHM poisoning.




tained from Sigma Chemical Co. USA) was dissolved 
in saline (1.0 mg/ml) (Figure 1).
Treatment of animals
Adult male and female Wistar rats (240–280 g 
body weight) were fed on a standard diet for laboratory 
rodents (Sljeme, Zagreb, Republic of Croatia). 
Animals had free access to water and were kept in 
macralone cages under controlled conditions (room 
temperature 21 °C, light and dark cycle exchanging 
every 12 hours). The rats (40 males and 40 females) 
were randomised in five control groups (n=3 each), 
and five experimental groups (n=5 each) receiving a 
single intraperitoneal (i.p.) dose of CHM (2.0 mg/kg 
body weight) on the first day of the experiment. The 
controls were given saline according to the same 
experimental design.
All animals were killed with coal gas 2, 3, 4, 5 
and 10 days after CHM/saline administration. Blood 
samples were obtained directly from the heart, and 
the adipose tissue was isolated from the epididymal 
(males) or parametrial (females) fat depots. Heart, 
brain and liver tissues were rinsed with saline. Plasma 
and tissue samples were frozen immediately after 
sampling at –20 °C until further processing. The tissue 
samples were homogenised (200 mg tissue/ml saline), 
and centrifuged at 2800 x g for 15 min to obtain the 
supernatant.
BuChE analysis
The catalytic activity of this enzyme in plasma 
and heart, brain, liver, and white adipose tissues 
was determined by spectrophotometry (17), using 
butyrylthiocholine (0.9 mM) (Sigma ChemCo, St. 
Louis, USA) as the substrate. Since heart, brain, and 
liver tissues contain BuChE and AChE, the BuChE 
assay was carried out with and without the specific 
BuChE inhibitor ethopropazine hydrochloride in the 
final concentration of 1.7 µM (Sigma ChemCo, St. 
Louis, USA). The catalytic activity of BuChE was 
calculated indirectly as the difference between the 
two measurements. The activity of the enzyme is 
expressed as µmol of substrate hydrolysed/min/ml 
for plasma and as µmol of substrate hydrolysed/min/g 
for the tissues. Since controls of the same sex did not 
differ in the catalytic activity of BuChE in either plasma 
or the tissues, we took the mean BuChE catalytic 
activity of all male or female rats as control values. 
Relative changes in the enzyme activity in the treated 
animals are presented as the percentage of activity of 
the respective control group.
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Figure 1 Structural formula of cycloheximide
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Statistical analysis
Data are shown as means and standard deviations 
(SD). Means, medians, and SD were calculated 
using a software package Statistics® for Windows 
Version 5.0 A (18). The statistical significance was 
determined by the parametric t–test and non–
parametric Kolmogorov–Smirnov two–sample test, 
where appropriate. The differences discussed in this 
paper were considered significant at P<0.05 level of 
significance.
RESULTS AND DISCUSSION 
The mean BuChE catalytic activity in plasma, 
liver and white adipose tissue was significantly (1.5–
3 times) higher in female than in male control rats. 
This sex–related difference is in accordance with the 
results published elsewhere (19, 20). These results 
show a negative modulatory effect of testosterone 
and a positive modulatory effect of estrogens on 
serum BuChE synthesis in the rat liver. The mode of 
action of both hormones on the enzyme synthesis in 
hepatocytes is not direct, but includes hypothalamic–
hypophyseal axis (21).
Tables 1 and 2 show the results of the BuChE 
assay in plasma, liver, heart, brain, and white adipose 
tissue of male and female rats obtained in our 
experiments. Although BuChE catalytic activity was 
significantly higher in female than in male controls 
in certain tissues, the percentage of BuChE catalytic 
activity observed in treated animals was consistent 
with control values for the same sex throughout the 
experiment.
Throughout the experiment, a single non–lethal 
dose of CHM (2.0 mg/kg body weight) significantly 
inhibited BuChE catalytic activity in the liver of both 
sexes. Since CHM inhibits protein synthesis (22) 
and BuChE is synthesised in the liver, the drop in 
the catalytic activity of BuChE may be attributed to 
the CHM inhibition of BuChE synthesis. The CHM 
inhibition of protein synthesis in the liver of rats given a 
lethal i.p. dose of CHM (10 mg/kg) was near complete 
after 3 hours and remained such for 9 hours (time to 
death was 14–20 hours after CHM) (23). As BuChE 
catalytic activity in our experiment did not recover for 
as long as 10 days after the treatment, we believe that 
the delay of the de novo synthesis of BuChE in rats is 
longer than reported elsewhere.
After the synthesis in the liver, BuChE is released 
into plasma. The biological half–life of BuChE in 
rat plasma is 9–11 days (24). After CHM treatment, 
BuChE catalytic activity in the plasma of rats of 
both sexes remained unchanged throughout the 
experiment. Although the synthesis of BuChE in the 
liver was completely inhibited by CHM, we believe that 
its relatively long half–life accounts for a maintained 
catalytic activity in plasma.
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Table 1 The catalytic activity of BuChE (Mean ± SD) and relative changes in the plasma and tissue of male rats killed 2, 3, 4, 5, and 10 days after 























































































Legend: significantly different from control groups, *t–test P<0.05; **t–test P<0.01; ***t–test P<0.001; +Kolmogorov–Smirnov test P<0.01; 
++Kolmogorov–Smirnov test P<0.001.
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A significant drop in BuChE activity was also 
observed in white adipose tissue, heart and brain 
(40–65% of control values). However, relative BuChE 
activity in these tissues was higher than in the liver. 
Cycloheximide is an imide whose metabolism is not 
fully understood. In the endoplasmatic reticulum 
of hepatocytes in humans and rats, imides are 
hydroxylated to more polar compounds with lower 
toxicity (25, 26). Literature has little data on BuChE 
catalytic activity in the adipose tissue and heart in 
CHM–treated animals. Gupta and Dettbarn (16) 
reported that subcutaneous administration of CHM 
(0.5 mg/kg for 4 days) did not significantly alter BuChE 
catalytic activity in either brain or other investigated 
tissues. It is likely that these authors administered 
subcutaneous no–effect doses of CHM for BuChE 
activity. We therefore believe that the difference 
between our and their results is due to a difference 
in doses. However, the route (intraperitoneal vs. 
subcutaneous administration), and the number 
of doses (multiple vs. single) can not be ruled out 
as reasons. As in the liver, the absence of BuChE 
recovery in the adipose tissue, heart and brain showed 
a long–lasting enzyme inhibition caused by CHM at 
the end of the experiment.
In our study, CHM was administered intraperito-
neally and was primarily absorbed through the portal 
circulation. In other words, it had to pass the liver 
before it reached other organs. The phenomenon 
of reduced pharmacological or toxicological effect 
of various xenobiotics in other organs due to their 
detoxification in the liver, known as the first–pass ef-
fect, is the plausible explanation for higher BuChE 
catalytic activity in white adipose tissue, heart and 
brain than in liver.
This is the first report on the effects of CHM on 
BuChE activity in animal plasma, liver, white adipose 
tissue and heart. Our findings on BuChE catalytic 
activity corroborate authors who suggest that CHM 
inhibits protein synthesis. This conclusion is seconded 
by the differences in BuChE catalytic activity between 
plasma and liver or other tissues, which indicate that 
it is the synthesis, rather than the enzymes catalytic 
activity which is being inhibited by CHM. The activity 
of BuChE in plasma is therefore not a suitable marker 
of CHM poisoning.
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Table 2 The catalytic activity of BuChE (Mean ± SD) and relative changes in the plasma and tissue of female rats killed 2, 3, 4, 5, and 10 days 























































































Legend: significantly different from control groups, *t–test P<0.05; **t–test p < 0.01; ***t–test P<0.001; +Kolmogorov–Smirnov test P<0.05; ++ 
Kolmogorov–Smirnov test P<0.01; +++Kolmogorov–Smirnov test P<0.001.
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Sažetak
DJELOVANJE CIKLOHEKSIMIDA NA AKTIVNOST BUTIRILKOLINESTERAZE IN VIVO
U ovom je istraživanju mjerena katalitička aktivnost enzima butirilkolinesteraze (BuChE) u plazmi, 
jetri, bijelom masnom tkivu, srcu i mozgu štakora tretiranih jednokratnom intraperitonealnom dozom 
cikloheksimida (2,0 mg/kg tjelesne težine, CHM). Katalitička aktivnost enzima izmjerena je u navedenim 
tkivima životinja obaju spolova koje su žrtvovane 2, 3, 4, 5 ili 10 dana nakon primjene CHM–a ili fiziološke 
otopine (kontrolna skupina). Značajno smanjenje katalitičke aktivnosti enzima BuChE izmjereno je u 
svim tkivima tretiranih životinja osim u plazmi gdje njegova aktivnost u životinja obaju spolova tijekom 
cjelokupnog istraživanja nije značajno odstupala od kontrolnih vrijednosti. Preostala katalitička aktivnost 
BuChE u jetrenome tkivu tretiranih životinja obaju spolova bila je 2–6%, dok je u masnom tkivu, srcu i 
mozgu aktivnost ovog enzima bila viša negoli u jetri, no statistički značajno različita od aktivnosti u istim 
tkivima kontrolnih životinja. Katalitička aktivnost BuChE u bijelome masnom tkivu, srcu i mozgu tretiranih 
mužjaka bila je 33–67, 49–62 i 14–71% u odnosu na aktivnost enzima u tkivima kontrolnih mužjaka, dok 
je u istim tkivima ženki taj raspon bio 24–82, 72–86 i 33–67%. Butirilkolinesteraza je enzim koji se većim 
dijelom sintetizira u jetri te izlučuje u cirkulaciju gdje mu je vrijeme polovičnog raspada 8–12 dana. Budući 
da CHM nije imao učinka na katalitičku aktivnost BuChE u plazmi štakora, a aktivnost enzima u jetri i 
drugim tkivima u kojima se vjerojatno sintetizira bila je značajno smanjena, može se zaključiti da CHM 
inhibira sintezu enzima, a ne njegovu katalitičku aktivnost. Stoga aktivnost BuChE u plazmi ne može biti 
pokazatelj otrovanja cikloheksimidom u ljudi.
KLJUČNE RIJEČI:  bijelo masno tkivo, jetra, mozak, plazma, sinteza proteina, srce, štakor
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